New study to track how kidney disease drugs work in real life
NCT ID NCT07481084
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will observe 80 adults with IgA nephropathy who are prescribed iptacopan or atrasentan as part of their routine care. Researchers will collect data on patient profiles, treatment patterns, and clinical outcomes over 24 months. The goal is to understand how these drugs perform in real-world settings and to contribute to a larger global analysis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- iptacopan and atrasentan
- What this could lead to
- If successful, this study could provide real-world evidence on how iptacopan and atrasentan work in everyday practice, potentially guiding better treatment decisions for IgA nephropathy.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by patient differences. It is also small (80 participants) and only follows patients for 24 months, limiting generalizability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mapping the Real-World treatment landscape for IgA nephropathy
- A simple test could forecast kidney disease progression
- Experimental drug aims to protect kidneys in inflammatory diseases
- Scientists probe kidney cell metabolism to unlock secrets of ANCA vasculitis
- Immune cell therapy takes on kidney disease
- Steroids for kidney disease: do they prevent failure Long-Term?